Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAL: Maintenance Pembrolizumab Duration in Advanced NSCLC
NCT05255302Phase 3Recruiting
- Sponsor
- IFCT
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: Overall Survival at 24 months. Started May 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05255302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255302.